Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 42.00 | |
2 mg | In stock | $ 58.00 | |
5 mg | In stock | $ 105.00 | |
10 mg | In stock | $ 166.00 | |
25 mg | In stock | $ 342.00 | |
50 mg | In stock | $ 547.00 | |
100 mg | In stock | $ 789.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 105.00 |
Description | PF-06260933 is a highly selective small-molecule MAP4K4 inhibitor with IC50s of 3.7 and 160 nM for kinase and cell, respectively. |
Targets&IC50 | MAP4K4:3.7 nM |
In vitro | Treatment with PF-06260933 significantly enhances the resistance of human aortic endothelial cells (EC) to TNF-α-induced increases in endothelial permeability in vitro. |
In vivo | Treatment with PF-06260933 does not modify plasma lipid content in a mouse model, yet it leads to decreased glucose levels, mirroring outcomes seen in whole-body-inducible Map4k4 knockout animals. Moreover, PF-06260933 administration results in either the attenuation of plaque progression or promotion of plaque regression in this model (46.0% versus 25.5%), alongside reductions in both plasma glucose and lipid content. |
Synonyms | PF-6260933, PF 6260933, PF6260933 |
Molecular Weight | 296.75 |
Formula | C16H13ClN4 |
CAS No. | 1811510-56-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 30 mg/mL
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PF-06260933 1811510-56-1 MAPK PF-6260933 PF06260933 inhibit MAP4K MAPK Kinase Kinase Kinase PF 6260933 PF 06260933 Inhibitor PF6260933 inhibitor